Journal Article (Review Article) DKFZ-2026-02194

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Molecular mechanisms and pathogenesis of MASH.

 ;  ;  ;  ;  ;

2026
Nature Publ. Group London [u.a.]

Nature 657(8130), 59 - 75 () [10.1038/s41586-026-10529-0]
 GO

Abstract: Metabolic dysfunction-associated steatotic liver disease (MASLD), including its progressive form metabolic dysfunction-associated steatohepatitis (MASH), represents the hepatic manifestation of metabolic syndrome and is increasingly recognized as a multi-organ disease. MASLD is now the most prevalent chronic liver disease worldwide and a rising indication for liver transplantation. MASLD incidence continues to increase, driven by sedentary lifestyles, the obesity epidemic and associated pathologies such as type 2 diabetes. MASH is a significant risk factor for fibrosis, cirrhosis and hepatocellular carcinoma (HCC)-a leading cause of cancer-related death. Over the past decade, substantial progress has been made in elucidating the molecular and cellular mechanisms driving MASLD initiation and progression. Key pathogenic processes include insulin resistance, genetic drivers, dysregulated hepatic lipid metabolism, lipotoxicity, adipose tissue dysfunction, immune-mediated inflammation, fibrogenesis and perturbations of the gut-liver axis. Increasingly, these mechanistic insights are informing clinical translation. Genetic risk variants and polygenic risk scores are beginning to enable improved risk stratification for disease progression and HCC. Furthermore, therapeutic strategies targeting defined metabolic pathways are emerging, including approaches that reduce hepatic lipogenesis or modulate mitochondrial metabolism. Here we highlight the state of the art of molecular and cellular mechanisms underlying MASH pathogenesis and its transition to HCC.

Keyword(s): Animals (MeSH) ; Humans (MeSH) ; Carcinoma, Hepatocellular: pathology (MeSH) ; Carcinoma, Hepatocellular: metabolism (MeSH) ; Disease Progression (MeSH) ; Insulin Resistance (MeSH) ; Lipid Metabolism (MeSH) ; Liver: metabolism (MeSH) ; Liver: pathology (MeSH) ; Liver Neoplasms: pathology (MeSH) ; Liver Neoplasms: metabolism (MeSH) ; Metabolic Syndrome: complications (MeSH) ; Metabolic Syndrome: metabolism (MeSH) ; Metabolic Syndrome: pathology (MeSH) ; Metabolic Syndrome: genetics (MeSH) ; Non-alcoholic Fatty Liver Disease: metabolism (MeSH) ; Non-alcoholic Fatty Liver Disease: pathology (MeSH) ; Non-alcoholic Fatty Liver Disease: genetics (MeSH)

Classification:

Note: #EA:D440#LA:D440#

Contributing Institute(s):
  1. Chronische Entzündung und Krebs (D440)
Research Program(s):
  1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2026
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Chemical Reactions ; Clarivate Analytics Master Journal List ; Current Contents - Agriculture, Biology and Environmental Sciences ; Current Contents - Life Sciences ; Current Contents - Physical, Chemical and Earth Sciences ; DEAL Nature ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 60 ; Index Chemicus ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection ; Zoological Record
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2026-09-07, last modified 2026-09-08



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)